Literature DB >> 10938

Metabolism of lorazepam.

H W Elliott.   

Abstract

The metabolism of lorazepam by man and four other species is reviewed. Lorazepam and its metabolites in blood, urine and faeces were identified by thin-layer and gas chromatography and by mass spectrometry. The principal metabolite in man, dog, pig and cat is the glucuronide, but the rat produces other metabolites after small doses of lorazepam, and significant amounts of the glucuronide only after high doses. Since all metabolites, except the glucuronide, occur in small quantities only in man, most studies in man have been confined to an estimation of gree and conjugated lorazepam. Blood concentrations of unconjugated lorazepam peak at 1-4 h, significant concentrations persisting for 24 h and decreasing slowly over the next 24 h. About 95% of a dose of lorazepam was accounted for in urine and faeces over a period of 5 days; 74.5% was excreted in the urine as lorazepam glucuronide and 13.5% as minor metabolites. The excretory half-life was 12 h. The blood concentrations and excretion rates are compatible with the clinical effects of lorazepam.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 10938     DOI: 10.1093/bja/48.10.1017

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  12 in total

1.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

Review 2.  Clinical pharmacokinetics of sedatives in neonates.

Authors:  E Jacqz-Aigrain; P Burtin
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

3.  CSF penetration and pharmacokinetics of midazolam.

Authors:  S Sjövall; J Kanto; J J Himberg; M Hovi-Viander; M Salo
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

Review 5.  Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 6.  Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal.

Authors:  Steven J Weintraub
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 7.  Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection.

Authors:  Linda L Liu; Michael A Gropper
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

Review 9.  The pharmacologic management of insomnia in patients with HIV.

Authors:  Toma S Omonuwa; Harold W Goforth; Xavier Preud'homme; Andrew D Krystal
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

Review 10.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.